Expectations of results from genome sequencing by end users are influenced by perceptions of uncertainty. This study aimed to assess uncertainties about sequencing by developing, evaluating, and implementing a novel scale. The Perceptions of Uncertainties in Genome Sequencing (PUGS) scale comprised ten items to assess uncertainties within three domains: clinical, affective, and evaluative. Participants (n=535) from the ClinSeq® NIH sequencing study completed a baseline survey that included the PUGS; responses (mean = 3.4/5, SD=0.58) suggested modest perceptions of certainty. A confirmatory factor analysis identified factor loadings that led to elimination of two items. A revised eight-item PUGS scale was used to test correlations with perce...
Aim: To explore how adults with a history of cancer perceive, appraise and manage uncertainty when d...
Aim: To explore how adults with a history of cancer perceive, appraise and manage uncertainty when d...
There is limited knowledge about cancer patients' experiences of uncertainty while waiting for genom...
Expectations of results from genome sequencing by end users are influenced by perceptions of uncerta...
Expectations of results from genome sequencing by end users are influenced by perceptions of uncerta...
Many variants that could be returned from genome sequencing may be perceived as ambiguous-lacking re...
PURPOSE: The scope of uncertainty in genome sequence information has no rival in health-care deliver...
Introduction—The scope of uncertainty in genomic sequence information has no rival in health care de...
Purpose Clinical next generation sequencing (CNGS) is introducing new opportunities and challenges i...
How individuals perceive uncertainties in sequencing results may affect their clinical utility. The ...
How individuals perceive uncertainties in sequencing results may affect their clinical utility. The ...
Introduction: The Knowledge of Genome Sequencing (KOGS) questionnaire was recently developed to meas...
Novel medical technologies, like large-panel genomic tumor testing (GTT), offer great promise but al...
PURPOSE: Clinical next-generation sequencing (CNGS) is introducing new opportunities and challenges ...
Novel medical technologies, like large-panel genomic tumor testing (GTT), offer great promise but al...
Aim: To explore how adults with a history of cancer perceive, appraise and manage uncertainty when d...
Aim: To explore how adults with a history of cancer perceive, appraise and manage uncertainty when d...
There is limited knowledge about cancer patients' experiences of uncertainty while waiting for genom...
Expectations of results from genome sequencing by end users are influenced by perceptions of uncerta...
Expectations of results from genome sequencing by end users are influenced by perceptions of uncerta...
Many variants that could be returned from genome sequencing may be perceived as ambiguous-lacking re...
PURPOSE: The scope of uncertainty in genome sequence information has no rival in health-care deliver...
Introduction—The scope of uncertainty in genomic sequence information has no rival in health care de...
Purpose Clinical next generation sequencing (CNGS) is introducing new opportunities and challenges i...
How individuals perceive uncertainties in sequencing results may affect their clinical utility. The ...
How individuals perceive uncertainties in sequencing results may affect their clinical utility. The ...
Introduction: The Knowledge of Genome Sequencing (KOGS) questionnaire was recently developed to meas...
Novel medical technologies, like large-panel genomic tumor testing (GTT), offer great promise but al...
PURPOSE: Clinical next-generation sequencing (CNGS) is introducing new opportunities and challenges ...
Novel medical technologies, like large-panel genomic tumor testing (GTT), offer great promise but al...
Aim: To explore how adults with a history of cancer perceive, appraise and manage uncertainty when d...
Aim: To explore how adults with a history of cancer perceive, appraise and manage uncertainty when d...
There is limited knowledge about cancer patients' experiences of uncertainty while waiting for genom...